NCT07683832 — The Affiliated Nanjing Drum Tower Hospital… neoantigen vaccine trial
Safety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccines Alone and in Combination With Toripalimab in Participants With Resected NSCLC
Registry record
| Registry ID | NCT07683832 ↗ |
|---|---|
| Lead sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
| Collaborators | Suzhou Abogen Biosciences Co., Ltd. |
| Phase | Phase EARLY_PHASE1 |
| Status | Not Yet Recruiting |
| Indication | Non-Small Cell Lung Cancer NSCLC |
| Enrollment | 50 participants (target) |
| Start date | 2026-07-28 |
| Primary completion | 2028-12-31 (est.) |
| Last registry update | 6 Jul 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07683832), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07683832?
NCT07683832 (Safety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccines Alone and in Combination With Toripalimab in Participants With Resected NSCLC) is registered on ClinicalTrials.gov as Phase EARLY_PHASE1, sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School.
Is NCT07683832 recruiting?
As of the 2026-07-06 registry update, NCT07683832 is listed as "Not Yet Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07683832?
The lead sponsor is The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. Collaborators: Suzhou Abogen Biosciences Co., Ltd..
What condition does NCT07683832 study?
The registered condition is Non-Small Cell Lung Cancer NSCLC. Primary completion is listed as 2028-12-31 (estimated).
Are results available for NCT07683832?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07683832.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.